UK health collaboration to tackle infection
This article was originally published in Scrip
The UK Clinical Research Collaborationhas pledged £9 million to fund the establishment of two infection research consortia in London and Oxford, to further collaborative research into the areas of hospital-acquired infections and antibiotic resistance. The Oxford consortium will focus on research on disease transmission with the aim of controlling their spread, using DNA sequencing techniques to speed up classifying and identifying them. This should make it easier to deal with local infection outbreaks, identify particularly virulent strains and help improve infection control guidelines, the UKCRC says. The London consortium, based at Imperial College London, will conduct research into individual and organisational behavioural change, modelling, epidemiology, rapid diagnosis and surveillance of selected infectious diseases to address and prevent healthcare-associated infection. Infections the consortia hope to tackle include tuberculosis, MRSA and Clostridium difficile. A second round of funding under the initiative is scheduled for late 2009.
You may also be interested in...
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.